Resources from JACI: In Practice During the COVID-19 Pandemic

Pandemic-related articles

COVID-19 Vaccination Approach Survey

Members of the American Academy of Allergy, Asthma & Immunology (AAAAI) based in the United States were recently surveyed regarding their approach to patients with possible allergy to COVID-19 mRNA vaccines. The survey was completed by 142 individuals (18% response rate).

Here is a summary of the results:

  • 92% were not administering the vaccine in their office, while 8% were administering in their office
  • 82% had evaluated patients to clear them for their first dose of the Pfizer or Moderna vaccine
    • In the evaluation of such patients, 50% did no testing, 49% did skin testing to polyethylene glycol, and 33% did skin testing to polysorbate
  • 55% had evaluated patients with reactions to their first dose of the Pfizer or Moderna vaccine
    • Among those who had not evaluated such patients, 85% had not received these referrals
  • Among patients evaluated for a reaction to their first dose, approaches by respondents were as follows:
    • 47% did no testing, 47% skin tested to polytheylene glycol, 36% skin tested to polysorbate, and 32% obtained a baseline tryptase
    • 69% used telehealth (especially telephone visits and video visits) in the evaluation
    • In patients with an immediate reaction to their first dose, a second dose was recommended by
      • 11%, whether or not the reaction was likely anaphylaxis
      • 40%, only in patients whose reaction was possibly allergic but not anaphylaxis
      • 40%, only in patients whose symptoms were not consistent with allergy
      • 9%, in no patients with prior reactions
    • In administering the second dose to individuals with reactions to their first dose
      • 61% used antihistamine pretreatment, 28% used no pretreatment, and 11% used other pretreatment
      • 84% administered the full dose, 13% a two-dose challenge, and 3% more than two doses
      • 74% recommended a 30 minute waiting period after the injection, and 23% recommended a 60 minute waiting period



Twitter Chats
Clinician Wellness During COVID-19: Maintaining Personal Health While Navigating Unexpected Challenges in Extraordinary Times

COVID-19: Pandemic Contingency Planning for Allergy and Immunology Clinic

#JACIIPCOVID
Follow @JACIInPractice on Twitter.



Special Edition Virtual Journal Clubs
The JACI: In Practice and the New Allergist/Immunologist Assembly (NAIA) provide special edition webinars to provide practical guidance to allergy/immunology clinicians during the COVID-19 pandemic.

Earn CME credit for these webinars!

Watch the recorded webinar discussing the JACI: In Practice article "A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services."

Watch the recorded webinar discussing the JACI: In Practice article, "AAAAI Work Group Report: COVID-19: Unmasking Telemedicine."

Watch the recorded webinar discussing two JACI: In Practice articles, "COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic" and "Telemedicine in the Era of COVID-19."



Expedited Reviews
JACI: In Practice offers expedited reviews for COVID-19 related articles that are relevant to the field of clinical allergy/immunology and deemed by the editors to be potentially valuable to our readers. Simply submit your manuscript or send a proposal to [email protected].



Articles
Read all of our pandemic-related articles we have published



If you are working remotely during the pandemic, we recommend reading this article by our Managing Editor, Dawn Angel.



AAAAI Resources for A/I Clinicians during the COVID-19 Pandemic

AAAAI Resources
Advertisement